Alkermes Plc (NASDAQ: ALKS)
Key Data Points
Alkermes Plc Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Alkermes Plc Company Info
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
News & Analysis
Alkermes Plc EPS Soars Past Forecasts
Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.
Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness relating to its external revenue streams.
Why Alkermes Stock Is Sinking Today
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors.
Why Alkermes Stock Is Jumping Today
The drugmaker beat Wall Street's expectations with its Q1 results.
Why Alkermes Stock Blasted 15% Higher Today
The biotech smashed analyst estimates in its final quarter of 2021.
Why Alkermes Stock Is Sinking Today
Johnson & Johnson partly ended two licensing agreements with the company.
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen isn't the only company whose shares should benefit from a breakthrough drug.
Why Shares of Alkermes Rose 18% Last Month
An agreement with an activist investor capped a busy month.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.